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EDITORIALS
Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus
The year 2019 marked a birthday of sorts for the field of
bronchiectasis. The disease was first described 200 years ago, in
1819, by the French physician and inventor of the stethoscope,
Rene´-The´ophile-Hyacinthe Lae¨nnec, in his book “Traite´ de
l’Auscultation Me´diate,” which was then translated over the next 2
years into the English version, “A Treatise on the Diseases of the
Chest and on Mediate Auscultation” (1).
Age brings wisdom, but the move toward maturity in the field
of bronchiectasis has been slow, held back by a perception that
the disease is mild, unimportant, or too heterogeneous to tackle.
Recent years have seen major advances in our understanding of
bronchiectasis, withmounting evidence regarding the effectiveness of
therapies such as macrolides and inhaled antibiotics, and increasing
research into the underlying biology (2). The components of the
classical vicious cycle are infection, inflammation, impaired
mucociliary clearance, and structural lung damage. It is notable that
for all of the progress we have made in the past 10 years, research
and therapeutic development have been largely concentrated in the
areas of infection and inflammation (3, 4).
A reading of Lae¨nnec’s original description of bronchiectasis
reminds us that mucus is, in many ways, the central feature of
bronchiectasis, or as he wrote, “the dilatation of the bronchi is only
met with in cases of chronic mucous catarrh. This single fact,
coupled with what we know respecting the long continuance of
mucous sputa in the spot where they have been secreted, enables us
to conceive the mode in which the disease is formed—a temporary
dilatation produced by voluminous sputum, is rendered permanent
by the constant and successive secretion” (1).
It is remarkable, therefore, how little research during the
renaissance of bronchiectasis has focused on the role of mucus and
mucociliary clearance. The study by Ramsey and colleagues
(pp. 661–670) published in this issue of the Journal is thus a timely
and important contribution (5).
Mucus is a protective coating that is secreted in healthy
airways and is composed of water, salt, and proteins. The correct
balance of these components is essential for the protective function
of the mucus layer. Among the proteins, mucins are the major
macromolecular component of the mucus gel in health. They are
glycoproteins that are responsible for the protective and clearance
properties of mucus (6). Several mucins have been described in
the lower respiratory tract of healthy subjects, with MUC5AC and
MUC5B being the most frequent (7). A dysregulation of mucin
secretion has been described in chronic inflammatory airway
diseases such as chronic obstructive pulmonary disease (COPD)
(7) and cystic fibrosis (8).
Ramsey and colleagues now characterize in detail the role of
mucins in bronchiectasis. In their study they used samples from
the BLESS (Bronchiectasis and Low-Dose Erythromycin Study)
cohort, which is a well-studied, randomized controlled trial
cohort that was originally used to evaluate the efficacy and safety
of erythromycin (3), and healthy control subjects. Using a
comprehensive array of analytical techniques, the authors
demonstrated that compared with samples from healthy subjects,
sputum from patients with bronchiectasis had a higher percentage
of solids, a higher DNA content, elevated total and individual
mucin expression, and increased viscosity, elasticity, and mucus
osmotic pressure. Together, these features suggest that, as in
COPD and cystic fibrosis, mucus is hyperconcentrated in
bronchiectasis.
MUC5B was the predominant mucin that was increased in the
sputum, followed by MUC5AC and MUC2. This is in contrast to
our pilot study of 50 patients, in which we found a correlation
between mucin concentrations and disease severity, but no
detectable levels of MUC5B (9). This discrepancy is likely
explained by the use of different types of samples (ultracentrifuged
supernatant vs. whole sputum) and the fact that we used
ELISA to detect mucin, whereas Ramsey and colleagues used
the gold-standard liquid chromatography/mass spectrometry
method.
The comprehensive assessment of mucins by Ramsey and
colleagues was then complemented by immunohistochemistry
staining of bronchial biopsies and evaluation of gene
expression. No differences were identified in the
idiopathic pulmonary fibrosis–associated MUC5B promoter
polymorphism between patients with bronchiectasis and
control subjects.
The authors’ ability to demonstrate a relationship between
mucins and disease severity in this cohort was limited by their
use of the BLESS study, which enrolled patients with two or
more exacerbations per year to enrich for patients likely to
benefit from macrolide therapy (3). Nevertheless, they did show
that the extent of radiological bronchiectasis was related to the
percentage of solids and osmotic pressure. Interestingly, there
was no meaningful relationship between any mucus
properties and FEV1% predicted, adding to a body of
literature showing that FEV1 has limited value as a marker of
bronchiectasis disease activity, being heavily influenced by
smoking and coexisting airways disease (10). Pseudomonas
aeruginosa infection is clearly associated with worse outcomes in
bronchiectasis, but mucus parameters in this study were
independent of the infecting pathogen. In contrast, all
mucus parameters were highly correlated to markers of
inflammation, including neutrophil elastase activity, IL-1b,
and CXCL8, consistent with evidence that high bacterial
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loads of all pathogens, not just P. aeruginosa, drive
neutrophilic inflammation (11). Neutrophilic inflammation
in vitro promotes mucin expression as well as degradation of
CFTR (cystic fibrosis transmembrane conductance regulator),
thereby increasing mucin production and impairing mucin
hydration (12, 13).
So, should we be treating mucin hyperconcentration?
Ramsey and colleagues demonstrated that the use of hypertonic
saline inhalation reduced mucus concentration by 25%, which
suggests at least that mucin hyperconcentration can be
therapeutically modified. Nevertheless, in keeping with the
heterogeneity of bronchiectasis, there was great variability
among the subjects with regard to mucus properties, suggesting
(as ever) that a one-size-fits-all approach is unlikely to be successful.
Dry-powder mannitol achieves mucus hydration and has been
tested in large randomized trials in bronchiectasis with mixed
results, and small studies of hypertonic versus isotonic saline
have yielded similarly conflicting results (14). The work presented
by Ramsey and colleagues may explain why individuals with
the greatest symptoms and inflammation, and therefore the
greatest mucus hyperconcentration, may be more likely to
respond to mucoactive drugs, in keeping with the emerging
“treatable traits” concept (15). Further research is required to
understand the mechanisms of mucus hyperconcentration in
bronchiectasis, including the potential role of genetic modifiers
such as CFTR mutations and other channelopathies, and
whether antiinflammatory and antiinfective treatments
that reduce bacterial load and inflammation also alter mucus
properties.
In summary, bronchiectasis was first described 200 years
ago as a disease of mucus accumulation and inflammation
leading to bronchial dilation (1). On this “birthday” of sorts, the
most comprehensive study to date of mucus properties suggests the
potential for new therapeutic development targeting mucus
hyperconcentration. Therapeutic development in bronchiectasis
has focused heavily in recent years on antiinfective and
antiinflammatory targets, but there are signs this is
changing, with large randomized trials now underway
testing the effectiveness of mucoactive drugs such as hypertonic
saline in bronchiectasis (ClinicalTrials.gov identifier:
NCT04140214).
The final word belongs to Lae¨nnec, who wrote in 1819, “This
affection being only a consequence and a complication of the
catarrh, it is evident that the only means we possess of restoring the
bronchi to their natural size is by diminishing the secretion of the
mucous membrane.”
We agree with Lae¨nnec and suggest that as we leave 2019
behind, it’s time to target the mucus! n
Author disclosures are available with the text of this article at
www.atsjournals.org.
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